BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of chronic and recurrent infections. BioTryp’s technology targets bacteria’s key defense mechanism, offering an alternative to traditional antibiotic treatments. The company’s small molecules are designed to block the communication process that […]

Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and autoimmune diseases. Bastion’s GRIT™ (Genetically Reconfigured & Improved Treg) platform technology utilises genetic engineering to restore and enhance the patient’s Treg function while also targeting Tregs to specific sites of […]

HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new class of genomic medicines that selectively block oncogene translation in hard-to-treat tumors. The company is led by a team whose work has generated 12 registered therapeutics, and founded by pioneers […]